Determination of antibiotic dosage adjustments in patients with renal impairment: Elements for success

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2285-2290

  Patel, Nimish ^a   Scheetz, Marc H ^b,c   Drusano, George L ^d   Lodise, Thomas P ^a,d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Kidney dysfunction; Optimal dosing strategies; Special populations

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXPOSURE; KIDNEY DISEASE; KIDNEY FUNCTION; MATHEMATICAL MODEL; MONTE CARLO METHOD;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG TOXICITY; HUMANS; INFUSIONS, INTRAVENOUS; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 77957886378     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq323     Document Type: Article

References (25)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
2. Bonapace CR, White RL, Frich LV et al. Differences in antimicrobial drug exposure in patients with various degrees of renal function based on recommendations from dosing references. Pharmacotherapy 2002; 22: 1097-104.
3. Brogard JM, Comte F, Spach MO et al. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function. Chemotherapy 1982; 28: 318-26.
4. Brogard JM, Kopferschmitt J, Spach MO et al. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol 1979; 19: 366-77.
5. Brogard JM, Pinget M, Dorner M et al. Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol 1975; 15: 666-73.
6. Kampf D, Schurig R, Weihermuller K et al. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Antimicrob Agents Chemother 1980; 18:81-7.
7. Leroy A, Humbert G, Fillastre JP. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother 1981; 19: 965-71.
8. Leroy A, Humbert G, Godin M et al. Pharmacokinetics of azlocillin in subjects with normal and impaired renal function. Antimicrob Agents Chemother 1980; 17: 344-9.
9. Randinitis EJ, Koup JR, Rausch G et al. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function. Antimicrob Agents Chemother 2001; 45: 2536-42.
10. Reitberg DP, Marble DA, Schultz RW et al. Pharmacokinetics of cefoperazone (2.0g) and sulbactam (1.0g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1988; 32: 503-9.
11. Welling PG, Craig WA, Bundtzen RW et al. Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother 1983; 23: 881-7.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 1-2.
13. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
14. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
15. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26: 1320-32.
16. Patel N, Scheetz MH, Drusano GL et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010; 54: 460-5.
17. Lodise TP Jr, Pypstra R, Kahn JB et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007; 51: 2378-87.
18. Lodise TP Jr, Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48: 4718-24.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Leary R, Jelliffe R, Schumitzky A et al. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Abstracts of the Fourteenth IEEE Symposium on Computer-Based Medical Systems, Bethesda, MD, 20P389-3IEEE Computer Society, Washington, DC, USA.
21. Kim MK, Xuan D, Quintiliani R et al. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin tazobactam. J Antimicrob Chemother 2001; 48: 259-67.
22. SheaKM, CheathamSC, Smith DWet al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 2009; 43: 1747-54.
23. D'Argenio DZ, Schumitzky A. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual, Biomedical Simulations Resource, University of Southern California, Los Angeles, CA, 1997.
24. Zosyn-Full Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2009.
25. Summary of Product Characteristics. Tazocin 2g/0.25g and 4g/0.5g Powder for Solution for Injection or Infusion. Taplow, UK: Wyeth Pharmaceuticals, 2009.